Antibody engineering for SFTS treatment: frontier progress and translational challenges
Frontiers in Microbiology · 05.08.2026 · 17
DOI: 10.3389/fmicb.2026.1888718 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Microbiology, online erschienen am 05.08.2026. Verfasst von Xinhan Yu und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nanjing University of Chinese Medicine.
Abstract (Originalsprache)
Severe Fever with Thrombocytopenia Syndrome (SFTS), a highly fatal tick-borne infectious disease caused by SFTS virus (SFTSV), currently lacks globally approved specific antiviral drugs or vaccines, although favipiravir was approved in Japan for SFTS treatment in June 2024 based on data from non-randomized, uncontrolled single-arm trials. Antibody engineering has emerged as a core strategy against SFTSV, leveraging its advantages of high specificity, potent neutralizing activity, and engineerability. This review systematically examines the mechanisms of action and preclinical progress of monoclonal antibodies, nanobodies, and bispecific antibodies (bsAbs) for SFTS treatment. It analyzes translational challenges—including immunogenicity, manufacturing processes, cost control, drug resistance, and clinical trial design—and proposes a strategic prioritization matrix and future research directions such as multispecific antibody development, artificial intelligence (AI)-assisted design, combination therapy strategies, and international multicenter collaboration. This review aims to provide a systematic reference for the clinical translation of SFTS antibody therapeutics.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
- Department of Anesthesiology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Förderung
- Nanjing University of Chinese Medicine
Zitieren
APA
Yu, X., Li, Y., Chang, S., Li, S., & Huang, H. (2026). Antibody engineering for SFTS treatment: frontier progress and translational challenges. Frontiers in Microbiology, 17. https://doi.org/10.3389/fmicb.2026.1888718
Vancouver
Yu X, Li Y, Chang S, Li S, Huang H. Antibody engineering for SFTS treatment: frontier progress and translational challenges. Frontiers in Microbiology. 2026;17. doi:10.3389/fmicb.2026.1888718
BibTeX
@article{Yu2026,
author = {Yu, Xinhan and Li, Youwang and Chang, Shuchen and Li, Sha and Huang, Huaying},
title = {Antibody engineering for SFTS treatment: frontier progress and translational challenges},
journal = {Frontiers in Microbiology},
year = {2026},
volume = {17},
doi = {10.3389/fmicb.2026.1888718}
}
EUVIMED